

CODOX-M/IVAC-R versus DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under

by Suheil Albert Atallah-Yunes, Matthew J. Rees, Thomas E. Witzig, Thomas M. Habermann, Javier Munoz, Madiha Iqbal, Ellen D. McPhail, and Grzegorz S. Nowakowski

Received: June 26, 2024.

Accepted: October 1, 2024.

Citation: Suheil Albert Atallah-Yunes, Matthew J. Rees, Thomas E. Witzig, Thomas M. Habermann, Javier Munoz, Madiha Iqbal, Ellen D. McPhail, and Grzegorz S. Nowakowski. CODOX-M/IVAC-R versus DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under.

Haematologica. 2024 Oct 10. doi: 10.3324/haematol.2024.286168 [Epub ahead of print]

Publisher's Disclaimer.

E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.

E-publishing of this PDF file has been approved by the authors.

After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal.

All legal disclaimers that apply to the journal also pertain to this production process.

CODOX-M/IVAC-R *versus* DA-EPOCH-R in double hit/triple hit lymphoma patients aged 60 years or under

Suheil Albert Atallah-Yunes¹, Matthew J. Rees¹, Thomas E. Witzig¹, Thomas M. Habermann¹, Javier Munoz², Madiha Iqbal³, Ellen D. McPhail⁴, Grzegorz S. Nowakowski¹

¹*Division of Hematology, Mayo Clinic, Rochester, MN, USA*

²*Division of Hematology, Mayo Clinic, Phoenix, AZ, USA*

³*Division of Hematology, Mayo Clinic, Jacksonville, FL, USA*

⁴*Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA*

Running head: CODOX-M/IVAC-R vs DA-EPOCH-R in DHL and THL

Correspondence:

Suheil Albert Atallah-Yunes, MD

Email Atallah-Yunes.SuheilAlbert@mayo.edu

Data sharing statement: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Author Contributions: GSN and SAAY contributed to the conception, design and analysis of the study and prepared the first draft of the manuscript; MJR contributed to data analysis; SAAY contributed to data collection and all authors contributed to data interpretation, provided critical and insightful comments, and approved the final manuscript.

Acknowledgement: The authors have no acknowledgements

Funding: No funding received for this work

Disclosures: J.Munoz **Consulting** – Pharmacyclics/Abbvie, Bayer, Gilead/Kite, Beigene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly; **Research funding** – Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene. **Honoraria** - Targeted Oncology, OncView, Curio, Genzyme, and Physicians' Education Resource. All other authors have no conflict of interest to disclose.

Abstract

Intensified chemoimmunotherapy regimens are often used in young patients with double hit and triple hit lymphoma (DHL/THL) despite no survival benefit compared to R-CHOP. Favorable retrospective reports on the application of CODOX-M/IVAC-R are subject to selection bias as only young fit patients can tolerate this treatment. We conducted a retrospective analysis to investigate outcome differences between CODOX-M/IVAC-R and DA-EPOCH-R in DHL/THL patients aged 60 years or younger. 113 patients were identified; CODOX-M/IVAC-R (N=49) and DA-EPOCH-R (N=64). 80% (39/49) achieved complete (CR) after completing CODOX-M/IVAC-R compared to 58% (37/64) with DA-EPOCH-R. The median follow-up was 5.3 years and 3.3 years for the CODOX-M/IVAC-R and DA-EPOCH-R group respectively. CODOX-M/IVAC-R demonstrated superior EFS on univariate (HR=0.54, 95%CI=0.31-0.97) and multivariable analysis adjusted for age, *BCL* translocation (*BCL2* vs *BCL6* vs both), IPI score and receipt of ASCT (aHR=0.52, 95%CI=0.29-0.93); however there was no significant influence on OS (aHR=0.92, 95%CI=0.46-1.84). The 1, 2 and 5 years EFS in the CODOX-M/IVAC-R group was 68.3%, 64.1% and 61.5% respectively compared to 52.4%, 48.9% and 39.5% respectively in the DA-EPOCH-R group. Primary refractory disease or relapse occurred in 33% (16/49) of CODOX-M/IVAC-R and 54% (35/64) of DA-EPOCH-R recipients, and produced median OS of 10.3 months and 33.7 months, respectively, indicating poor outcomes in the CODOX-M/IVAC-R subgroup with R/R disease. More patients were able to receive subsequent salvage therapies in the DA-EPOCH-R group. No patients died of regimen toxicity and the rates of CNS relapse and therapy related hematologic neoplasms were similar in both groups.

Introduction

Patients with high-grade B-cell lymphoma (HGBL) including double hit lymphoma (DHL) and triple hit lymphoma (THL) have a more aggressive clinical presentation, shorter response to conventional R-CHOP therapy, and higher frequency of extra-nodal and central nervous system (CNS) involvement compared patients with diffuse large B cell lymphoma-not otherwise specified (DLBCL-NOS).¹⁻⁴ The median overall survival (OS) has been reported to range between 4.5 months to 34 months in various series.^{1, 5-8} However, the 2022 revision of the WHO classification of lymphoid neoplasms (WHO-HAEM5) has redefined the HGBL category such that it comprises only aggressive B cell lymphomas that are genetically double hit (DH) with dual *MYC* and *BCL2* rearrangements on fluorescence in situ hybridization (FISH) studies (MYC-BCL2 DHL) or triple hit (TH) with rearrangements in *MYC*, *BCL2* and *BCL6* (MYC-BCL2-BCL6 THL).^{9, 10} In the WHO-HAEM5 classification, DHLs with rearrangements in *MYC* and *BCL6* but lacking *BCL2* rearrangements (MYC-BCL6 DHL) are reclassified according to morphology as either DLBCL-NOS or HGBL-NOS mainly due to the heterogeneity in their gene expression and molecular profile compared to MYC-BCL2 DHL.¹⁰⁻¹³ Additionally, it has been reported that prognosis of patients with MYC-BCL6 DHL may be better than those with MYC-BCL2 DHL.⁸

There is no standardized induction chemoimmunotherapy regimen for patients with DHL/THL. However, the associated poor outcomes have led to the utilization of intensified chemoimmunotherapy regimens despite the lack of prospective trials demonstrating survival benefit over conventional R-CHOP therapy in this subgroup of patients. Induction regimens that have been used include R-CHOP with or without adjuvant autologous stem cell transplant (ASCT) or the more intensive regimens such as DA-EPOCH-R, CODOX-M/IVAC-R, R-Hyper-CVAD and R-ACVBP¹⁴. The results of previous studies show conflicting results as to whether the more intensive regimens are better than standard R-CHOP.^{1, 14-16}

The use of hyper-fractionated alkylating agents and incorporating multiple agents that penetrate the CNS such as in the CODOX-M/IVAC-R regimen may have beneficial treatment outcomes in MYC driven aggressive lymphomas. CODOX-M/IVAC-R is highly effective in the treatment of Burkitt lymphoma, but this comes with significant toxicity.¹⁷⁻¹⁹ Some reports have documented favorable outcomes with this therapy in patients with HGBL.²⁰⁻²² In a retrospective study, CODOX-M/IVAC-R produced more favorable outcomes compared to R-CHOP and other intensified regimens (DA-EPOCH-R, R-Hyper-CVAD), with a statistically significant improvement in the 12 months event free survival (EFS) in the 17 patients who received CODOX-M/IVAC-R compared to the 59 patients who received R-CHOP, DA-EPOCH-R and Hyper-CVAD (72% vs 39% , P= 0.04); this lost statistical significance after adjusting for age. A trend towards an improved OS (HR, 0.37; 95% CI, 0.11–1.23; P=0.10) was observed, although a selection bias may have played a role as most patients who received CODOX-M/IVAC-R were younger than 60 years.²²

Young patients with DHL/THL frequently receive one of the intensive chemoimmunotherapy regimens whereas patients over 60 years of age often receive R-CHOP. There are important differences between CODOX-M/IVAC-R and DA-EPOCH-R. CODOX-M/IVAC-R must be given in the hospital and even once discharged the patient needs to stay close to the treatment center. It does have the advantage of only 4 cycles of therapy. DA-EPOCH-R can be given as an outpatient with an infusion pump but patients often elect hospitalization; 6 cycles is the standard. Based on these facts and the prior highlighted reports demonstrating favorable outcomes with CODOX-M/IVAC-R but with the possibility of age-related selection bias; we aimed to study the outcome difference between patients who received CODOX-M/IVAC-R and individuals who received DA-EPOCH-R for treatment of DHL/THL in a larger cohort of patients who are 60 years or younger at diagnosis in an effort to mitigate age related selection bias.

Methods

This retrospective study received approval by the Mayo Clinic Institutional Review Board. Patient cases were identified through Epic electronic medical records chart review including individuals diagnosed with DHL/THL between July 15th 2010 and October 19th 2023 and received medical care at the Mayo Clinic. Over this period, selection between DA-EPOCH-R and CODOX-M/IVAC-R in young patients with DHL/THL was based on the preference of different Mayo physicians. DHL/THL cases were defined by morphology and FISH results. Morphology was determined by pathology report and could have features of HGBL, large B cell lymphoma or in between. Stratification into DHL or THL relied on FISH results. DHL was defined genetically via FISH as having rearrangement of *MYC* along with *BCL2* (*MYC-BCL2* DHL) or *BCL6* (*MYC-BCL6* DHL). THL was defined as having rearrangement of *MYC* as well as *BCL2* and *BCL6* (*MYC-BCL2-BCL6* THL). Inclusion criteria were patients who were 60 years old or younger at diagnosis of DHL/THL and either received CODOX-M/IVAC-R or DA-EPOCH-R for induction treatment. DHL/THL transformed from low grade indolent B cell lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) even if received prior lines of therapy for low grade B cell lymphoma were included. Patients with no available FISH reports in the chart were excluded. Cell of origin was determined by the Hans classifier.²³

Medical records were also reviewed to obtain data on salvage treatment, development of therapy related myelodysplastic syndrome (MDS)/ acute myeloid leukemia (AML), CNS relapse and cause of death.

Data were analyzed using 'R' statistical software, version 4.3.2. Quantitative discrete and continuous variables were described as a median and interquartile range; categorical variables were described as a number and percentage. Group comparisons were performed using Fischer's exact or Chi-squared tests. Quantitative discrete variables were compared using the Wilcoxon rank-sum test.

Univariate and multivariate analyses of factors associated with survival were performed using the Cox proportional hazards regression model. A priori pre-specified prognostic factors included in the model were age, receipt of consolidation with autologous stem-cell transplantation, international prognostic index (IPI) for DLBCL and *BCL* translocation status (*BCL2* vs *BCL6* vs both). A two-side *p* value of <0.05 was considered statistically significant. EFS was defined as the time from diagnosis to progression, relapse, re-treatment after initial chemotherapy, or death of any cause. OS was defined as the time from diagnosis to death of any cause or to last follow-up.

Results:

Patient, therapy, and tumor characteristics

One hundred and thirteen patients were identified, 57% (64/113) were treated with DA-EPOCH-R and 43% (49/113) received CODOX-M/IVAC-R. The median number of administered DA-EPOCH-R cycles was six (IQR 6-5). Fourteen percent (9/64) of the DA-EPOCH-R group did not complete intended therapy including eight patients who experienced disease progression while receiving treatment and one patient who stopped treatment due to declining performance status. The median number of CODOX-M/IVAC-R cycles administered was four (IQR 4-4). Four percent (2/49) of the CODOX-M/IVAC-R group did not complete intended treatment including one patient who had disease progression on treatment and one patient who stopped therapy due to treatment intolerance. Table 1 illustrates patient and disease characteristics in each treatment group. The percentage of patients with at least one comorbidity according to the Charlson Comorbidity Index (CCI) was similar between the DA-EPOCH-R and CODOX-M/IVAC-R groups (13% vs. 14%, respectively). The median CCI score (excluding age and a history of lymphoma) for the DA-EPOCH-R and CODOX-M/IVAC-R groups were both zero [IQR: 0-1]. Two patients in the DA-EPOCH-R group and no patients in the CODOX-M/IVAC-R group had >1 comorbidity. Types of comorbidities were well balanced between the two groups,

except for cardiac disease history (myocardial infarction or congestive heart failure) which was reported in four patients in the DA-EPOCH-R group but in none of the CODOX-M/IVAC-R group.

Therapy outcomes

The percentage of patients who achieved complete remission (CR) on end of treatment (EOT) positron emission tomography-computed tomography scan (PET-CT) in the CODOX-M/IVAC-R group and DA-EPOCH-R group was 80% (39/49) and 58% (37/64) respectively. The median follow-up time was 5.3 and 3.3 years for the CODOX-M/IVAC-R and DA-EPOCH-R group respectively. CODOX-M/IVAC-R was associated with superior EFS on univariate (HR=0.54, 95%CI=0.31-0.97) and multivariable analysis adjusted for age, *BCL* translocation status (*BCL2* vs *BCL6* vs both), IPI and receipt of consolidation ASCT (aHR=0.52, 95%CI=0.29-0.93). However, there was no significant association with OS (aHR=0.92, 95%CI=0.46-1.84). The EFS for the CODOX-M/IVAC-R group at 1, 2 and 5 years was 68.3, 64.1 and 61.5% respectively compared to 52.4, 48.9 and 39.5% respectively in the DA-EPOCH-R group (p=0.035). (Figure 1)

In light of the WHO22-HAEM5 classification,¹⁰ we examined whether the 16 patients with MYC-BCL6 DHL have more favorable outcomes with either therapy. On univariate analysis compared to DHL patients with *BCL2* rearrangements, patients with BCL6-DHL had comparable EFS (HR=0.69, 95%CI=0.29, 1.65, p=0.41) and OS (HR=1.06, 95%CI=0.40-2.81, p=0.92). These results were unchanged when adjusting for the treatment received; EFS (aHR=0.70, 95%CI=0.30-0.95, p=0.41) and OS (aHR=1.06, 95%CI=0.40-2.84, p=0.90). When analysis was restricted to only patients with a MYC-BCL6 rearrangement (n=16), there was no significant difference in EFS (p=0.2) or OS (p=0.22) between the two treatment groups on univariate Cox proportional hazards modelling. We also evaluated whether transformed DHL/THL patients had more favorable outcomes with either therapy. On univariate analysis, transformed DHL/THL was associated with comparable outcomes to de-novo disease in EFS (HR=1.37,

95%CI=0.76-2.50, p=0.30) and OS (HR=1.37, 95%CI=0.66-2.84, p=0.41). On multivariable analysis adjusted for treatment received, transformed disease had similar results again: EFS (HR=1.30, 95%CI=0.72=2.37, p=0.38) and OS (HR=1.36, 95%CI=0.65-2.84, p=0.42).

Twenty two percent (N=11/49) of CODOX-M/IVAC-R and 17% (11/64) of DA-EPOCH-R patients received ASCT consolidation after induction therapy. ASCT produced superior EFS compared to no ASCT on univariate (HR=0.30, 95%CI=0.14-1.13, p=0.011) and multivariable analysis adjusted for age, treatment and BCL translocation status (aHR=0.28, 95%CI=0.11-0.70, p=0.0069). However, ASCT was used almost exclusively in patients who attained a CR following induction (except for 1 patient who obtained a PR) and when the effect of ASCT was restricted to patients who had obtained a CR following induction therapy, there was no significant difference observed in EFS (HR=0.69, 95%CI=0.23-2.13, p=0.52) and OS (HR=1.3, 95%CI=0.38-4.45, p=0.68).

Outcomes for patients with refractory/relapsed disease

Thirty three percent (16/49) of the CODOX-M/IVAC-R patients had refractory or relapsed (R/R) disease. This included patients who did not have a CR on EOT PET-CT (10/49 including 9 with refractory disease and 1 with partial response) or who had relapsed disease (6/49, 12%). The percentage of patients with R/R disease in the DA-EPOCH-R group was 54% (35/64) including 42% (27/64) who did not achieve CR on EOT PET-CT (22 refractory, 3 partial response (PR), 1 stable disease, 1 undocumented response) and 13% (8/64) who relapsed later. The median OS for the patients who had R/R disease after receiving CODOX-M/IVAC-R was 10.3 months compared to 33.7 months in the R/R DA-EPOCH-R group (Figure 2). More patients in the DA-EPOCH-R with R/R disease were able to receive salvage therapy and proceed to undergo ASCT, allogeneic stem cell transplant and/or receive CAR T cells. (Figure3)

Prior lines of therapy in patients with transformed disease

Among the 18 patients with transformed disease who received DA-EPOCH-R, 39% (N=7) had previously undergone treatment for indolent B-cell lymphoma. Of these, five patients had received one prior line of therapy (four with bendamustine + rituximab and one with rituximab alone), while two had undergone four lines of therapy each. One of these two patients had received rituximab, CVP chemotherapy, ibritumomab tiuxetan, and bendamustine plus rituximab (BR), and the other patient had received chlorambucil + prednisone, CVP-R, radiation, and BR.

In the CODOX-M/IVAC-R group, 11 patients had transformed disease, with 55% (N=6) having received prior therapy for indolent B-cell lymphoma. Of these six, five had received one line of therapy (three with BR, one with CHOP chemotherapy, and one with radiation alone), and one had received two lines of therapy (ABVD chemotherapy and RICE chemoimmunotherapy followed by ASCT consolidation).

Therapy related hematologic neoplasm, CNS relapse and cause of death

None of the patients who received CODOX-M/IVAC-R or DA-EPOCH-R died of regimen related toxicity, excluding 1 patient who died of therapy related AML in the CODOX-M/IVAC-R group.

The DA-EPOCH-R included intrathecal chemotherapy for CNS disease prophylaxis, however, 13% (8/64) received additional high dose methotrexate (HDMTX) for CNS prophylaxis. CNS relapses occurred in 4.7% (3/64) of patients who received DA-EPOCH-R; all of whom died of disease. One patient treated with DA-EPOCH-R had CNS disease at initial diagnosis. All 3 patients with CNS relapses received prior intrathecal chemotherapy for CNS prophylaxis and 1 also received HDMTX. Among the 31% (20/64) of patients who died in the DA-EPOCH-R group, 17 patients died of lymphoma progression while 3 died of other causes including 1 patient who died of lung cancer, 1 patient died of COVID 19 pneumonia, and 1 patient died of progressive multifocal leukoencephalopathy. The incidence of

developing therapy related hematologic neoplasm (AML/MDS) was 4.7% (3/64) in the DA-EPOCH-R arm.

Fifteen patients (30.6%) died in the CODOX-M/IVAC-R group. Four of the 15 patients died of causes unrelated to lymphoma including 1 patient died of CAR T cell therapy related complications (despite achieving response), 1 died of an unrelated neurological syndrome, 1 died of allogeneic stem cell transplant complications and 1 patient died of therapy related AML. Four percent (2/49) developed CNS relapse without having CNS disease at initial diagnosis. One patient treated with CODOX-M/IVAC-R had CNS disease at initial diagnosis, did not respond to treatment and was palliated. In addition, 4.1% (2/49) developed therapy related AML/MDS.

Discussion

There is currently no standard induction regimen choice for treatment of patients with DHL/THL. The results of previous studies show conflicting results as to whether the more intensive regimens are better than standard R-CHOP. A large retrospective study (n=129) by Oki et al showed more favorable outcomes in DHL/THL patients treated with intensive treatment regimens compared to R-CHOP.¹⁶ Petrich et al showed a superior median progression free survival (PFS) in patients who underwent induction treatment with DA-EPOCH-R (P=0.0463), R-Hyper-CVAD (0.001) and CODOX-M/IVAC-R (P=0.036) compared to R-CHOP however no survival benefit was observed.¹ In the systematic meta-analysis by Howlett et al, there was reduced risk of progression with DA-EPOCH-R compared to R-CHOP (relative risk reduction of 34%; P = 0.032) with no OS benefit.¹⁵ In a prospective phase 2 study that involved 24 patients with DHL treated with DA-EPOCH-R, the 4-year OS rate after a median follow up of 55.6 months was 82% in the DHL/THL group, higher than historical data.²⁴ However, real-world

studies of DHL patients treated with DA-EPOCH-R showed inferior survival outcomes compared to the data from the prospective phase 2 study.²⁵⁻²⁷ Additionally, the role of consolidation with ASCT after an intensive chemoimmunotherapy regimen has shown benefit only if R-CHOP is the upfront regimen.²⁸

Some reports have documented favorable outcomes with CODOX-M/IVAC-R in patients with HGBL.²⁰⁻²² Sun et al reported on 25 patients who received CODOX-M/IVAC-R including 16 patients who had subsequent consolidation with ASCT. The 2-year PFS and 2-year OS in these 16 patients were 60% and 82% respectively.²¹ A single-center series demonstrated favorable outcomes when using CODOX-M/IVAC-R for treatment of DHL/THL compared to R-CHOP and intensive regimens including DA-EPOCH-R and R-Hyper CVAD.²² However, the CODOX-M/IVAC-R sample size was limited (n=17). Additionally, the possibility of age-related selection bias leading to superior outcomes in the CODOX-M/IVAC-R was acknowledged in the report as most of the patients (12/17) who received CODOX-M/IVAC-R were 60 years old or younger at diagnosis compared to the DA-EPOCH-R group who only had 3 patients aged 60 years or younger.

Our findings in a large sample size limited to young DHL/THL patients revealed that despite an improved EFS in patients who received CODOX-M/IVAC-R, there was no difference in OS between patients treated with CODOX-M/IVAC-R and individuals who received DA-EPOCH-R. A possible attribution to these findings may be explained by other results we demonstrated in which higher proportion of patients in the DA-EPOCH-R group who had R/R after induction treatment were able to undergo salvage chemotherapy and proceed with subsequent ASCT, receive CAR T cells and/or undergo allogeneic stem cell transplantation. The rates of treatment related mortality were low, with only one patient dying of a therapy-related myeloid neoplasm during follow-up. In general, both groups were well balanced in terms of age and performance status however patients in the CODOX-M/IVAC-R group tended to have higher IPI scores and stage. EFS remained superior in the CODOX-M/IVAC-R group on multivariate analysis after adjusting for IPI and stage.

Although CODOX-M/IVAC-R is known for its high toxicity rates; there were no treatment related deaths in our CODOX-M/IVAC-R group, except for one late death secondary to a therapy related myeloid neoplasm. In the phase 2 UK NCRI trial evaluating CODOX-M/IVAC-R in high risk DLBCL patients, treatment was well tolerated. However, the five deaths attributed to treatment toxicity primarily occurred among patients aged ≥ 50 years with ECOG PS of 3.²⁰ Thirteen patients aged > 60 years were among the participants in the trial. In our study, none of the patients in the CODOX-M/IVAC-R group had an ECOG PS of ≥ 3 , and only two patients aged ≥ 50 years had ECOG PS 2. Therefore, it is possible that this difference in patient characteristics along with the younger patient population in our study could have contributed to the lower treatment mortality rate we observed. Although comorbidities were infrequent and generally balanced between the treatment groups, there was a notable difference in cardiac disease history reported in the DA-EPOCH-R group. Additionally, no patients in the CODOX-M/IVAC-R group had more than one comorbidity. Thus, we cannot exclude the possibility that the favorable comorbidity profile along with the absence of cardiac disease history in the CODOX-M/IVAC-R group may have attributed to the better EFS and absence of treatment related deaths in the CODOX-M/IVAC-R group.

Despite the CODOX-M/IVAC-R regimen having agents that can penetrate the CNS, the rate of CNS relapse was similar between the DA-EPOCH-R and CODOX-M-IVAC-R groups. However, it is worth mentioning that a higher percentage of patients in the CODOX-M/IVAC-R group had a high-risk CNS IPI score (10% vs. 3%) and intermediate-risk CNS IPI score (76% vs. 66%) compared to the DA-EPOCH-R group.

A strength of this study is it comprises a large number of patients who received CODOX-M/IVAC-R and a relatively large number of patients with DHL/THL whom are 60 years old or younger, thus mitigating selection bias related to age. Additionally, we included only patients whose FISH and pathology reports were available for our review. The limitations of this study lie in its retrospective

nature. Although this study is not a randomized trial, selection between DA-EPOCH-R and CODOX-M/IVAC-R in young patients with DHL/THL and proceeding with ASCT consolidation was based on the preference of different Mayo clinic physicians. As discussed earlier, both groups were similar in age, performance status and CCI scores; however, the more prominent history of cardiac disease in the DA-EPOCH-R group cannot be ruled out as a source of selection bias for this regimen. Another limitation was that not all FISH and pathology studies were centrally reviewed at our institute. Some FISH studies were performed outside our institute and in some cases, there was inadequate tissue to perform a complete FISH probe analysis. Although our cohort of patients who are 60 years old or younger may be larger than the ones published previously, it is still inadequate to draw definitive conclusions especially on small sub analysis groups such as patients who had MYC-BCL6 DHL or patients who had transformed disease. However, we did not identify a difference in clinical outcome based on MYC-BCL6 or transformed disease status.

In conclusion, we found no difference in OS between young patients with DHL/THL who underwent induction treatment with DA-EPOCH-R and those treated with CODOX-M/IVAC-R. However, the CODOX-M/IVAC-R group had an improved EFS, higher CR rate and no increased treatment related mortality compared to the DA-EPOCH-R group. Patients who have R/R disease after induction treatment with DA-EPOCH-R were more able to receive salvage treatment with ASCT, CAR T cell therapy and allogeneic stem cell transplantation. In light of this, some patients may elect to pursue treatment with CODOX-M/IVAC-R in a well monitored hospitalized setting with careful monitoring for toxicity as this may potentially spare them receiving subsequent therapies in the future. Prospective and larger cohort studies will be required to further investigate these findings. Furthermore, it will be important to look into whether incorporating novel targeted and immunotherapy agents currently being investigated in clinical trials for first-line treatment of large B cell lymphoma could replace the need for using intensified regimens in high-risk patients including those with DHL/THL.

References

1. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. *Blood*. 2014;124(15):2354-2361.
2. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. *Blood*. 2009;114(17):3533-3537.
3. Staton AD, Cohen JB. A Clinician's Approach to Double-Hit Lymphoma: Identification, Evaluation, and Management. *J Oncol Pract*. 2016;12(3):232-238.
4. Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. *Haematologica*. 2007;92(10):1335-1342.
5. Bertrand P, Bastard C, Maingonnat C, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. *Leukemia*. 2007;21(3):515-523.
6. Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. *Blood*. 2009;114(11):2273-2279.
7. Kanungo A, Medeiros LJ, Abruzzo LV, Lin P. Lymphoid neoplasms associated with concurrent t(14;18) and 8q24/c-MYC translocation generally have a poor prognosis. *Mod Pathol*. 2006;19(1):25-33.

8. Ye Q, Xu-Monette ZY, Tzankov A, et al. Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma. *Oncotarget*. 2016;7(3):2401-2416.
9. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Leukemia*. 2022;36(7):1720-1748.
10. Kurz KS, Ott M, Kalmbach S, et al. Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Concepts. *Cancers (Basel)*. 2023;15(8):2285.
11. Chapuy B, Stewart C, Dunford AJ, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nat Med*. 2018;24(5):679-690.
12. Collinge B, Ben-Neriah S, Chong L, et al. The impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC. *Blood*. 2021;137(16):2196-2208.
13. Cucco F, Barrans S, Sha C, et al. Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit. *Leukemia*. 2020;34(5):1329-1341.
14. Récher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. *Lancet*. 2011;378(9806):1858-1867.

15. Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. *Br J Haematol.* 2015;170(4):504-514.
16. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. *Br J Haematol.* 2014;166(6):891-901.
17. Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. *Ann Oncol.* 2002;13(8):1264-1274.
18. Phillips EH, Burton C, Kirkwood AA, et al. Favourable outcomes for high-risk Burkitt lymphoma patients (IPI 3-5) treated with rituximab plus CODOX-M/IVAC: Results of a phase 2 UK NCRI trial. *EJHaem.* 2020;1(1):133-141.
19. Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. *J Clin Oncol.* 1996;14(3):925-934.
20. McMillan AK, Phillips EH, Kirkwood AA, et al. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial. *Ann Oncol.* 2020;31(9):1251-1259.
21. Sun H, Savage KJ, Karsan A, et al. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation. *Clin Lymphoma Myeloma Leuk.* 2015;15(6):341-348.

22. McPhail ED, Maurer MJ, Macon WR, et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. *Haematologica*. 2018;103(11):1899-1907.
23. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*. 2004;103(1):275-282.
24. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. *Lancet Haematol*. 2018;5(12):e609-e617.
25. Doderio A, Guidetti A, Marino F, et al. Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. *Haematologica*. 2022;107(5):1153-1162.
26. Doderio A, Guidetti A, Tucci A, et al. Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. *Leukemia*. 2019;33(4):1047-1051.
27. Nelles R, Morris K, Scott A, Kennedy G. Dose-adjusted EPOCH-R is a safe and well tolerated outpatient treatment regimen in double-hit lymphoma. *Intern Med J*. 2023;53(5):773-778.
28. Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. *J Clin Oncol*. 2017;35(20):2260-2267.

Tables

Table1 Patient and disease characteristics in each treatment group

Characteristic	Therapy			p-value ²
	Overall, N = 113 ¹	DA-R-EPOCH, N = 64 ¹	R-CODOX-M/IVAC-R, N = 49 ¹	
Age	54 (44, 57)	55 (46, 57)	53 (44, 57)	0.4
Female	61 (54%)	30 (47%)	31 (63%)	0.08
ECOG				0.6
0-1	107 (96%)	62 (97%)	45 (94%)	
2	5 (4.5%)	2 (3.1%)	3 (6.3%)	
Unknown	1	0	1	
IPI				0.027
0-1	27 (24%)	21 (33%)	6 (12%)	
2	50 (44%)	27 (42%)	23 (47%)	
3-4	36 (32%)	16 (25%)	20 (41%)	
Extra-nodal disease	89 (79%)	48 (75%)	41 (84%)	0.3
>1 extra-nodal site	40 (35%)	21 (33%)	19 (39%)	0.5
Bone marrow involvement	12 (11%)	7 (11%)	5 (10%)	>0.9
DHL vs THL				0.3
DHL	82 (73%)	49 (77%)	33 (67%)	
THL	31 (27%)	15 (23%)	16 (33%)	
Translocations				0.5
MYC-BCL2	66 (58%)	40 (63%)	26 (53%)	
MYC-BCL6	16 (14%)	9 (14%)	7 (14%)	
MYC-BCL2-BCL6	31 (27%)	15 (23%)	16 (33%)	
Stage				0.020

I/II	17 (15%)	14 (22%)	3 (6.1%)	
III/IV	96 (85%)	50 (78%)	46 (94%)	
Immunophenotype (Hans algorithm)				0.2
GCB	104 (95%)	62 (98%)	42 (91%)	
Non-GCB	5 (4.6%)	1 (1.6%)	4 (8.7%)	
Unknown	4	1	3	
<i>De novo</i> vs transformed				0.5
<i>De novo</i>	84 (74%)	46 (72%)	38 (78%)	
Transformed	29 (26%)	18 (28%)	11 (22%)	
ASCT consolidation	22 (19%)	11 (17%)	11 (22%)	0.5

¹Median (IQR); n (%)


²Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

Figure Legends

Figure 1 Comparison of outcomes based on frontline treatment regimens in patients with double-hit lymphoma (DHL) or triple-hit lymphoma (THL) who are ≤ 60 years old. (A) Event-free survival (EFS) stratified by treatment regimen, comparing CODOX-M/IVAC-R and DA-EPOCH-R. (B) Overall survival (OS) stratified by treatment regimen, comparing CODOX-M/IVAC-R and DA-EPOCH-R.


Figure 2 Overall survival (OS) is compared between patients who achieved sustained complete remission (CR) after induction treatment and those with relapsed/refractory disease. (A) Patients treated with CODOX-M/IVAC-R. (B) Patients treated with DA-EPOCH-R.

Figure 3 The number of patients who experienced refractory/relapsed disease within each of the DA-EPOCH-R and CODOX-M/IVAC-R groups and received subsequent therapy including individuals who underwent ASCT, allogeneic stem cell transplant and/or received CAR T cells.

A

No. at Risk

	0	1	2	3	4	5	6	7
DA-R-EPOCH	64	31	24	15	10	7	2	1
R-CODOX-M-IVAC	49	32	30	27	19	16	9	8


B

No. at Risk

	0	1	2	3	4	5	6	7
DA-R-EPOCH	64	53	38	24	17	13	7	3
R-CODOX-M-IVAC	49	36	33	28	20	17	9	8

A

Overall survival: R-CODOX-M-IVAC




No. at Risk

■	33	31	30	27	19	16	9	8
■	16	5	3	1	1	1	0	0

B

Overall survival: DA-R-EPOCH



No. at Risk

■	29	26	21	13	9	6	1	0
■	35	27	17	11	8	7	6	3

Relapsed or refractory disease (n=51)

DA-EPOCH-R (n=35)

CODOX-M/IVAC-R (n=16)

No subsequent therapy (n=1)

Salvage therapy (n=34)

No subsequent therapy (n=2)

Salvage therapy (n=14)

Patients who underwent ASCT, allogeneic stem cell transplant and/or received CAR T cells (n=23)

- ASCT (n=3)
- Allogeneic stem cell transplant (n=2)
- CAR T cell therapy (n=14)
- ASCT and CAR T cell therapy (n=2)
- CAR T and allogeneic stem cell (n=2)

Patients who underwent ASCT, allogeneic stem cell transplant and/or received CAR T cells (n=7)

- ASCT (n=1)
- Allogeneic stem cell transplant (n=1)
- CAR T cell therapy (n=3)
- CAR T and allogeneic stem cell (n=2)

Best response to CAR T

- CR (n=10)
- PR (n=4)
- Refractory (n=3)
- Unknown (n=1)

Best response to CAR T

- CR (n=1)
- PR (n=2)
- Refractory (n=1)
- Unknown (n=1)